120 related articles for article (PubMed ID: 38747153)
41. Risk factors for acute kidney injury after radical nephrectomy and inferior vena cava thrombectomy for renal cell carcinoma.
Shin S; Han Y; Park H; Chung YS; Ahn H; Kim CS; Cho YP; Kwon TW
J Vasc Surg; 2013 Oct; 58(4):1021-7. PubMed ID: 23591189
[TBL] [Abstract][Full Text] [Related]
42. Renal cell carcinoma in the solitary kidney: an analysis of complications and outcome after nephron sparing surgery.
Ghavamian R; Cheville JC; Lohse CM; Weaver AL; Zincke H; Blute ML
J Urol; 2002 Aug; 168(2):454-9. PubMed ID: 12131287
[TBL] [Abstract][Full Text] [Related]
43. Transperitoneal laparoscopic radical nephrectomy for patients with dialysis-dependent end-stage renal disease: an analysis and comparison of perioperative outcome.
Bird VG; Shields JM; Aziz M; De Los Santos R; Ayyathurai R; Ciancio G
Urology; 2010 Jun; 75(6):1335-42. PubMed ID: 20035985
[TBL] [Abstract][Full Text] [Related]
44. Long-term outcome of multiple ipsilateral renal tumours found at the time of planned nephron-sparing surgery.
Krambeck A; Iwaszko M; Leibovich B; Cheville J; Frank I; Blute M
BJU Int; 2008 Jun; 101(11):1375-9. PubMed ID: 18454793
[TBL] [Abstract][Full Text] [Related]
45. Can partial nephrectomy preserve renal function and modify survival in comparison with radical nephrectomy?
Medina-Polo J; Romero-Otero J; Rodríguez-Antolín A; Domínguez-Esteban M; Passas-Martínez J; Villacampa-Aubá F; Lora-Pablos D; Gómez De La Cámara A; Díaz-González R
Scand J Urol Nephrol; 2011 Mar; 45(2):143-50. PubMed ID: 21247272
[TBL] [Abstract][Full Text] [Related]
46. ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinoma.
Kaffenberger SD; Morgan TM; Stratton KL; Boachie AM; Barocas DA; Chang SS; Cookson MS; Herrell SD; Smith JA; Clark PE
BJU Int; 2012 Dec; 110(11 Pt B):E641-6. PubMed ID: 22958439
[TBL] [Abstract][Full Text] [Related]
47. Oncological outcomes of minimally invasive partial versus minimally invasive radical nephrectomy for cT1-2/N0/M0 clear cell renal cell carcinoma: a propensity score-matched analysis.
Simone G; Tuderti G; Anceschi U; Papalia R; Ferriero M; Misuraca L; Minisola F; Mastroianni R; Costantini M; Guaglianone S; Sentinelli S; Gallucci M
World J Urol; 2017 May; 35(5):789-794. PubMed ID: 27578234
[TBL] [Abstract][Full Text] [Related]
48. Overall survival and oncological outcomes after partial nephrectomy and radical nephrectomy for cT2a renal tumors: A collaborative international study from the French kidney cancer research network UroCCR.
Reix B; Bernhard JC; Patard JJ; Bigot P; Villers A; Suer E; Vuong NS; Verhoest G; Alimi Q; Beauval JB; Benoit T; Nouhaud FX; Lenormand C; Hamidi N; Cai J; Eto M; Larre S; El Bakhri A; Ploussard G; Hung A; Koutlidis N; Schneider A; Carrouget J; Droupy S; Marchal S; Doerfler A; Seddik S; Matsugasumi T; Orsoni X; Descazeaud A; Pfister C; Bensalah K; Soulie M; Gill I; Flamand V;
Prog Urol; 2018 Mar; 28(3):146-155. PubMed ID: 29331568
[TBL] [Abstract][Full Text] [Related]
49. Three-dimensional tumour volume and cancer-specific survival for patients undergoing nephrectomy to treat pT1 clear-cell renal cell carcinoma.
Jorns J; Thiel DD; Lohse CM; Williams A; Arnold ML; Cheville JC; Leibovich BC; Parker AS
BJU Int; 2012 Oct; 110(7):956-60. PubMed ID: 22300498
[TBL] [Abstract][Full Text] [Related]
50. Overall survival and renal function after partial and radical nephrectomy among older patients with localised renal cell carcinoma: a propensity-matched multicentre study.
Chung JS; Son NH; Lee SE; Hong SK; Lee SC; Kwak C; Hong SH; Kim YJ; Kang SH; Byun SS
Eur J Cancer; 2015 Mar; 51(4):489-497. PubMed ID: 25576517
[TBL] [Abstract][Full Text] [Related]
51. Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery.
Lerner SE; Hawkins CA; Blute ML; Grabner A; Wollan PC; Eickholt JT; Zincke H
J Urol; 1996 Jun; 155(6):1868-73. PubMed ID: 8618276
[TBL] [Abstract][Full Text] [Related]
52. Renal cell carcinoma (RCC) arising in native kidneys of dialyzed and transplant patients: are they different entities?
Gigante M; Neuzillet Y; Patard JJ; Tillou X; Thuret R; Branchereau J; Timsit MO; Terrier N; Boutin JM; Sallusto F; Karam G; Barrou B; Chevallier D; Mazzola CR; Delaporte V; Doeffler A; Kleinclauss F; Badet L; ;
BJU Int; 2012 Dec; 110(11 Pt B):E570-3. PubMed ID: 22726451
[TBL] [Abstract][Full Text] [Related]
53. A comparison of overall survival and perioperative outcomes between partial and radical nephrectomy for cT1b and cT2 renal cell carcinoma-Analysis of a national cancer registry.
Venkatramani V; Koru-Sengul T; Miao F; Nahar B; Prakash NS; Swain S; Punnen S; Ritch C; Gonzalgo M; Parekh D
Urol Oncol; 2018 Mar; 36(3):90.e9-90.e14. PubMed ID: 29254672
[TBL] [Abstract][Full Text] [Related]
54. Exploratory Subgroup Analyses of Renal Function and Overall Survival in European Organization for Research and Treatment of Cancer randomized trial of Nephron-sparing Surgery Versus Radical Nephrectomy.
Scosyrev E; Messing EM; Sylvester R; Van Poppel H
Eur Urol Focus; 2017 Dec; 3(6):599-605. PubMed ID: 28753863
[TBL] [Abstract][Full Text] [Related]
55. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies.
Mir MC; Derweesh I; Porpiglia F; Zargar H; Mottrie A; Autorino R
Eur Urol; 2017 Apr; 71(4):606-617. PubMed ID: 27614693
[TBL] [Abstract][Full Text] [Related]
56. Routine adrenalectomy in patients with locally advanced renal cell cancer does not offer oncologic benefit and places a significant portion of patients at risk for an asynchronous metastasis in a solitary adrenal gland.
Weight CJ; Kim SP; Lohse CM; Cheville JC; Thompson RH; Boorjian SA; Leibovich BC
Eur Urol; 2011 Sep; 60(3):458-64. PubMed ID: 21514718
[TBL] [Abstract][Full Text] [Related]
57. Predictive characteristics for disease recurrence and overall survival in non-metastatic clinical T1 renal cell carcinoma - results from the National Swedish Kidney Cancer Register.
Almdalal T; Karlsson Rosenblad A; Hellström M; Kjellman A; Lindblad P; Lundstam S; Sundqvist P; Ljungberg B
Scand J Urol; 2023; 57(1-6):67-74. PubMed ID: 36520023
[TBL] [Abstract][Full Text] [Related]
58. Cytoreductive nephron-sparing surgery does not appear to undermine disease-specific survival in patients with metastatic renal cell carcinoma.
Hutterer GC; Patard JJ; Colombel M; Belldegrun AS; Pfister C; Guille F; Artibani W; Montorsi F; Pantuck AJ; Karakiewicz PI
Cancer; 2007 Dec; 110(11):2428-33. PubMed ID: 17941033
[TBL] [Abstract][Full Text] [Related]
59. Elective nephron sparing surgery should become standard treatment for small unilateral renal cell carcinoma: Long-term survival data of 216 patients.
Becker F; Siemer S; Humke U; Hack M; Ziegler M; Stöckle M
Eur Urol; 2006 Feb; 49(2):308-13. PubMed ID: 16359779
[TBL] [Abstract][Full Text] [Related]
60. Oncologic outcomes of nephron-sparing surgery in patients with T1 multifocal renal cell carcinoma.
Li G; Zhu D; Gao H; Chen H; Li Y; Niu Y
Clin Transl Oncol; 2019 Jun; 21(6):760-765. PubMed ID: 30443869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
